Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00102102 · ClinicalTrials.gov registry record

Role of Substance P in Post-Traumatic Stress Disorder

A clinical trial of Post Traumatic Stress Disorder, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
40
Enrollment target
1
Study location

NCT00102102 is a study of Post Traumatic Stress Disorder that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 40 participants, below the 1,117-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00102102, a study of Post Traumatic Stress Disorder, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

This study will examine the role of substance P, a chemical messenger in the brain, in post-traumatic stress disorder (PTSD), a chronic anxiety disorder. PTSD can develop after exposure to a terrifying event or ordeal, such as a violent personal assault, natural or human-caused disaster, accident, or military combat. Substance P is a peptide that may be important in the response to certain psychiatric and neurological diseases and conditions, including anxiety. Healthy normal volunteers and people with PTSD who are between 18 and 65 years of age may be eligible for this study. Candidates are screened with a physical examination, blood and urine tests, pregnancy test for women who can become pregnant, and a neuropsychological evaluation. Participants undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning. An optional lumbar puncture (spinal tap) is also requested. PET Scanning PET uses small amounts of a radioactive chemical called a tracer that "labels" active areas of the brain. The tracer used in this study is \[18F\]SPA-RQ. For the procedure, the subject lies still on the scanner bed. A special mask is fitted to the head to help keep the subject's head still during the scan so the images will be clear. A 20-minute "transmission" scan is done before the radioactive tracer is injected to provide measures of the brain that will help in the precise calculation of information from subsequent scans. After the tracer is injected through a needle in the arm, pictures are taken continuously for about 2 hours. Then, 20- to 40-minute images are taken every hour until about 5 hours after the injection. MRI Scanning An MRI scan is scheduled at some time within 1 year of the PET scan. MRI uses a magnetic field and radio waves to obtain images of body tissues and organs. The subject lies still on a table inside the tunnel-like MRI scanner. Earplugs are worn to muffle loud noises that occur during the scanning. The maximum duration of the

Conditions Studied

Post Traumatic Stress Disorder

Interventions

  • DRUG [18F]SPA-RQ

Study Locations (1)

Maryland

  • National Institute of Mental Health (NIMH) - Bethesda

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2005-01
Est. Completion 2006-01

Sponsor

National Institute of Mental Health (NIMH)

343 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00102102

The ClinicalTrials.gov registry entry for NCT00102102 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,117-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 1 intervention - of which [18F]SPA-RQ is the first listed.

NCT00102102 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00102102 about?

NCT00102102 is a clinical study titled "Role of Substance P in Post-Traumatic Stress Disorder". This study will examine the role of substance P, a chemical messenger in the brain, in post-traumatic stress disorder (PTSD), a chronic anxiety disorder. PTSD can develop after exposure to a terrifying event or ordeal, such as a violent personal assault, natural or human-caused disaster, accident, o...

What is the current status of trial NCT00102102?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2005-01. Estimated completion is 2006-01.

What conditions does trial NCT00102102 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT00102102?

The interventions under investigation include: [18F]SPA-RQ (DRUG).

Who is sponsoring clinical trial NCT00102102?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00102102 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Post Traumatic Stress Disorder

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.